Browse studies

Find your next paid study

7 recruiting studies matching your filters

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with m…

Castration-Resistant Prostatic CancerMetastasis

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06863272

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

Background: Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new w…

Prostatic CancerProstatic NeoplamsProstatic Hyperplasia+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT03354416

Phase 1

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the …

Prostate CancerMetastatic Castration-resistant Prostate CancerCastration Resistant Prostatic Cancer

Estimated

~$10 – $8,750

Janux TherapeuticsNCT05519449

Phase 1

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants wi…

Advanced Solid TumorAdvanced CancerMetastatic Cancer+19 more

Estimated

~$10 – $7,500

MacroGenicsNCT06242470

Phase 1

A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC)…

Metastatic Castration-Resistant Prostatic Cancer

Estimated

~$10 – $7,500

T.O.A.D. Oncology SANCT07258407

Observational

High-dose Rate (HDR) Brachytherapy Boost With Stereostatic Body Radiation Therapy (SBRT) to Prostate and Pelvic Nodes for the Initial Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer

The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of Stereostatic Body Radiation Therapy (SBRT) to pros…

Prostatic Cancer

Estimated

~$10 – $6,250

University of NebraskaNCT05754580

Phase 2

A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer

The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and …

Prostate CancerRefractory CancerCastration Resistant Prostatic Cancer

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT04337580